The single-cell analysis firm plans to use the proceeds to fund general corporate activities and potentially acquire businesses, products, or technologies.
The revenues come entirely from CGI's discovery services as its divested biopharma services and clinical lab units were considered discontinued operations.
The companies said that they will combine NeuroFlow’s mental health integration platform and Genomind's Professional PGx Express pharmacogenomics service.
Results from some 4,200 GWAS suggest a significant subset of genetic loci contribute to multiple complex traits, though the type of overlap further varied at the gene and SNP levels.
Canaccord Genuity began coverage of Castle Biosciences with a Buy rating and a $26 price target, while SVB Leerink assigned an Outperform rating and a $28 price target.
Last week, GenomeWeb readers were most interested in a report of cases where genetic testing was incorrectly recommended, ordered, interpreted, or used.
The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.
The clinic will offer comprehensive DNA sequencing, interpretation, and reporting of disease-associated genes for healthy adults and their children.
The award will go to Jocelyn Silvester of Children's Hospital Boston, to fund transcriptomics research on intestinal inflammation caused by gluten.
The FDA has granted accelerated approval to Rozlytrek as a treatment for adult and adolescent patients with NTRK fusion-positive cancers.
The $10 million initiative will include scientists from the University of California's campuses, as well as from governmental and nongovernmental organizations.
Industry players, faced with vague communications from the agency, scramble to decipher regulatory expectations and criticize the agency for trying to control PGx knowledge.
The researchers identified genes that specifically extend the lifespan of neurons and found genes that increase the number of neurites in the brain.
The combined company will use RNA-based tools to enhance drug development by identifying the right patients for oncology drugs and potentially improving drug response rates.
The team saw risky mutations in colorectal cancer, polyp, and Lynch syndrome-related genes in almost 4 percent of CRC patients diagnosed at 72 years old, on average.
In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.
The firm, which is working to reaccelerate its test validation effort, incurred a loss of $5.4 million, or $.10 per share, slightly above the analysts' consensus estimate.
The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.
The firms announced a deal to develop services and products for sequencing-based T cell and B cell receptor profiling in the US and Europe.
By analyzing metagenomic sequences found in thousands of human mouth and gut samples, researchers tracked down almost 45.7 million distinct microbial genes.
The revenue growth was driven in part by sales generated by Australian reagent maker TGR Biosciences, which Expedeon acquired in May last year.
The FDA center of excellence has engaged the technology vendor to incorporate real-world evidence into regulatory decision-making for precision oncology treatments.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.